Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: A phase II trial

Journal of Interferon and Cytokine Research

Volumn 31, Issue 5, 2011, Pages 433-440

  Borden, Ernest C ^a   Jacobs, Barbara ^a   Hollovary, Emese ^a   Rybicki, Lisa ^a   Elson, Paul ^a   Olencki, Thomas ^a   Triozzi, Pierre ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CXCL11 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FAS LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN A;

ADULT; AGED; AIM2 GENE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; BST2 GENE; CHILL; CLINICAL ARTICLE; CUTANEOUS METASTATIC MELANOMA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FATIGUE; FEVER; G1P2 GENE; G1P3 GENE; GENE; HUMAN; HYPOPHOSPHATEMIA; IFI27 GENE; IFITM2 GENE; IL22RA1 GENE; INJECTION SITE REACTION; IRF7 GENE; LEUKOPENIA; LYMPHOCYTOPENIA; MELANOMA; MX1 GENE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; SERUM; SIDE EFFECT; THROMBOCYTOPENIA; UVEA MELANOMA; WEIGHT REDUCTION; XAF1 GENE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-BETA; MALE; MELANOMA; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79955768337     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0054     Document Type: Article

References (59)

1. Abdi EA, Tan YH, McPherson TA. 1988. Natural human interferon-beta in metastatic malignant melanoma. A phase II study. Acta Oncol 27(6b):815-817.
2. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182(1):155-162.
3. Aronica SM, Raiber L, Hanzly M, Kisela C. 2009. Antitumor/ antiestrogenic effect of the chemokine interferon inducible protein 10 (IP-10) involves suppression of VEGF expression in mammary tissue. J Interferon Cytokine Res 29(2):83-92.
4. Ascierto PA, Kirkwood JM. 2008. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62.
5. Ashkenazi A. 2008. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7(12): 1001-1012.
6. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. 2008. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SKMEL- 28 melanoma cells to interferons (IFNs) or Apo2L/ TRAIL. Oncogene 27(4):490-498.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. 2009. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206.
8. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990. (Pubitemid 350201788)
9. Borden EC, Williams BR. 2011. Interferon-stimulated genes and their protein products: What and how? J Interferon Cytokine Res 31(1):1-4.
10. Borden EC. 2005. Review: Milstein Award lecture: Interferons and cancer: Where from here? J Interferon Cytokine Res 25(9): 511-527. (Pubitemid 41395839)
11. Brennecke S, Deichmann M, Naeher H, Kurzen H. 2005. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15(6):515-522. (Pubitemid 44124263)
12. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. 2000. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20(10):857-866.
13. Chawla-Sarkar M, Leaman DW, Borden EC. 2001. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7(6):1821-1831. (Pubitemid 32708654)
14. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. 2002. IFNbeta pretreatment sensitizes human melanoma cells to TRAIL/ Apo2 ligand-induced apoptosis. J Immunol 169(2):847-855. (Pubitemid 34753441)
15. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. 2003. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249. (Pubitemid 36749609)
16. D'Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr., Borden EC. 1996. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 157(9):4100-4108. (Pubitemid 126449322)
17. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69(6):912-920. (Pubitemid 32577892)
18. Der SD, Zhou A, Williams BR, Silverman RH. 1988. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95(26):15623-15628.
19. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. 2008. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233-52339.
20. Dunn GP, Koebel CM, Schreiber RD. 2006. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6(11):836-848. (Pubitemid 44631652)
21. Falschlehner C, Schaefer U, Walczak H. 2009. Following TRAIL's path in the immune system. Immunology 127(2):145-154.
22. Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr. 2006. Interferon gammainducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 13(1): 125-133. (Pubitemid 43117654)
23. Ferrantini M, Capone I, Belardelli F. 2007. Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 89(6-7):884-893. (Pubitemid 47001642)
24. Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC. 1989. Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst 81(14):1061-1068. (Pubitemid 19175140)
25. Gomi K, Morimoto M, Nakamizo N. 1984. Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice. J Pharmacobiodyn 7(12): 951-961. (Pubitemid 15174853)
26. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161(6):2833-2840. (Pubitemid 28425704)
27. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25(3):349-360. (Pubitemid 44354220)
28. Honda K, Yanai H, Takaoka A, Taniguchi T. 2005. Regulation of the type I IFN induction: A current view. Int Immunol 17(11): 1367-1378. (Pubitemid 41631313)
29. Hosseini-Moghaddam SM, Mousavi A, Alavian SM. 2009. Is {beta}-interferon a promising therapeutic option for the management of hepatitis C? J Antimicrob Chemother 63(6):1097-1103.
30. Ida N, Uenishi N, Kajita A, Satoh Y. 1982. Antitumor effect of human fibroblast interferon on the growth of human melanoma cells implanted in nude mice. Gann 73(6):952-960. (Pubitemid 13187279)
31. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. 2000. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virusrelated liver cancer. Hepatology 32(2):228-232. (Pubitemid 30614654)
32. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. 2003. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 37(3): 610-621. (Pubitemid 36258783)
33. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. 1992. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 84(15):1185-1190.
34. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. 2002. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20(17):3703-3718. (Pubitemid 34983231)
35. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. 1996. Interferon alfa-2b adjuvant therapy of highrisk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7-17. (Pubitemid 26019991)
36. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. 2008. Metaanalysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26(4):527-534. (Pubitemid 351264344)
37. Krasagakis K, Garbe C, Krüger S, Orfanos CE. 1991. Effects of interferons on cultured human melanocytes in vitro Interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 97(2):364-372.
38. Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A, Yi T, Williams BR, Borden EC. 2003. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: Greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res 23(12):745-756. (Pubitemid 38041446)
39. Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, Faber P, Bukowski R, Tong K, Borden EC. 2007. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: A second member of the interferon-alpha family. Clin Pharmacol Ther 81(3):354-361. (Pubitemid 46364486)
40. McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJ. 2003. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res 13(4): 379-387. (Pubitemid 36900700)
41. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferonlike cytokines, and their receptors. Immunol Rev 202:8-32. (Pubitemid 39576902)
42. Rani MR, Xu Y, Lee JC, Shrock J, Josyula A, Schlaak J, Chakraborthy S, Ja N, Ransohoff RM, Rudick RA. 2009. Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta. Ann N Y Acad Sci 1182:58-68.
43. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. 1999. A phase I study of recombinant interferonbeta in patients with advanced malignant disease. Clin Cancer Res 5(12):3990-3998. (Pubitemid 30013775)
44. Ray PS, Jia J, Yao P, Majumder M, Hatzoglou M, Fox PL. 2009. A stress-responsive RNA switch regulates VEGFA expression. Nature 457(7231):915-919.
45. Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, Wagner TC, Perez HD, Salamon H, Croze E. 2008. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 28(5):317-331. (Pubitemid 351725305)
46. Ruzicka FJ, Jach ME, Borden EC. 1987. Binding of recombinantproduced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains. J Biol Chem 262(33): 16142-16149. (Pubitemid 17165206)
47. Ryuke Y, Mizuno M, Natsume A, Suzuki O, Nobayashi M, Kageshita T, Matsumoto K, Saida T, Yoshida J. 2003. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Res 13(4):349-356. (Pubitemid 36900696)
48. Sarna GP, Figlin RA, Pertcheck M. 1987. Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma. J Biol Response Mod 6(4):375-378. (Pubitemid 17112187)
49. Schiller JH, Willson JK, Bittner G, Wolberg WH, Hawkins MJ, Borden EC. 1986. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J Interferon Res 6(6):615-625. (Pubitemid 17024427)
50. Schnyder-Candrian S, Strieter RM, Kunkel SL, Walz A. 1995. Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. J Leukoc Biol 57(6):929-935.
51. Schonfeld A, Nitke S, Schattner A, Wallach D, Crespi M, Hahn T, Levavi H, Yarden O, Shoham J, Doerner T, et al. 1984. Intramuscular human interferon-beta injections in treatment of condylomata acuminata. Lancet 1(8385):1038-1042. (Pubitemid 14148933)
52. Sidky YA, Borden EC. 1987. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47(19):5155-5161. (Pubitemid 17146488)
53. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG; Idiopathic Pulmonary Fibrosis Biomarkers Study Group. 2004. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 170(2):133-140. (Pubitemid 38925158)
54. Stroncek DF, Basil C, Nagorsen D, Deola S, Aricó E, Smith K, Wang E, Marincola FM, Panelli MC. 2005. Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med 3:24.
55. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. 2008. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res 28(12):733-740. (Pubitemid 352773930)
56. Ugurel S, Rappl G, Tilgen W, Reinhold U. 2001. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577-583. (Pubitemid 32112873)
57. Wicovsky A, Siegmund D, Wajant H. 2005. Interferons induce proteolytic degradation of TRAILR4. Biochem Biophys Res Commun 337(1):184-190. (Pubitemid 41393777)
58. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. 2007. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422-2228.
59. Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, Carson WE 3rd. 2008. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res 14(18):5900-5906.